

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/38693> holds various files of this Leiden University dissertation.

**Author:** Gvozdenovic, Emilia

**Title:** Monitoring rheumatoid arthritis

**Issue Date:** 2016-03-31

## **Chapter 6**

# **DAS steered therapy in clinical practice; cross-sectional results from the METEOR database**

E.Gvozdrenović , R. Wolterbeek, D. van der Heijde, T.W.J. Huizinga, C.F.  
Allaart, R. Landewé.

*BMC Musculoskeletal Disorders; January 2015*

## ABSTRACT

### Objective

Little is known on how well targeted treatment, for instance targeting towards low DAS, is implemented in clinical practice. Our aim was to evaluate treatment adjustments in response to DAS in RA patients in clinical practice.

### Methods

We used data from one referral centre, multiple rheumatologists, from the METEOR database. Generalized Estimating Equations (GEE) were used to assess whether in case of non-low disease activity (DAS>2.4) treatment intensifications in DMARD therapy occurred (change or increase in dose or number of DMARDs, including synthetic (s)DMARDs, biologic (b)DMARDs and corticosteroids compared to the visit before). Determinants of not intensifying the treatment when DAS>2.4 were investigated using GEE.

### Results

5.157 registered visits of 1.202 patients were available for the analyses. A DAS>2.4 was weakly (OR: 1.19; 95%CI 1.07 to 1.33) associated with a treatment intensification. In 69% (n=3.577) of the visits patients were in low disease activity. In 66% (n=1.028) of the visits with DAS>2.4 treatment was not intensified. These patients had a higher tender joint count and received more often methotrexate plus a bDMARD, or csDMARD monotherapy, as compared to patients that received treatment intensification.

### Conclusion

In the majority of visits in the METEOR database patients were already in a state of low disease activity, reflecting appropriate treatment intensity. When DAS was greater than 2.4, treatment was often not intensified due to high tender joint count or specific treatment combinations. This data suggest that while aiming for low DAS, physicians per patient weigh whether all DAS elements indicate disease activity or will respond to DMARD adjustment or not, and make treatment decisions accordingly.

## INTRODUCTION

The aim of treatment in rheumatoid arthritis (RA) is to achieve low disease activity or remission using a ‘treat to target’ (tight control) approach in which the disease activity of patients is monitored intensively and measured frequently with composite measures.<sup>1-3</sup> Treatment intensity can be adjusted by changing DMARDs or by increasing the dose and/or number of anti-rheumatic drugs, including synthetic (s)DMARDs and biologic (b)DMARDs and corticosteroid.<sup>4</sup> Since treatment to target and tight control have been proven to result in better clinical and radiological outcomes than routine care,<sup>5-11</sup> these concepts are at the basis of the current recommendations for the management of rheumatoid arthritis in daily practice. When sustained remission or low disease activity is achieved and medication is tapered or discontinued and following patients and tight control is important as half of the patient may flare with decreasing medication.<sup>12,13</sup> Despite the fact that rheumatologists have reported to use treat-to-target in daily practice,<sup>14-16</sup> some studies have suggested that targeted treatment may not be widely practiced yet<sup>17,18</sup>. Besides, it is well known that limited adherence to guidelines is prevalent in many chronic conditions, such as atrial fibrillation, hypertension and osteoporosis.<sup>19-21</sup>

We used the Measurement of Efficacy of Treatment in the ‘Era of Outcome’ in Rheumatology (METEOR) database,<sup>22</sup> to investigate the association between level of the DAS and whether or not physicians adjusted treatment with sDMARDs and bDMARDs and corticosteroids in patients with RA in daily clinical practice.

## METHODS

### Patients

For the current cross-sectional analyses we have used data from METEOR, which is an international prospective database aiming to improve tight monitoring and treatment to target in patients with rheumatic diseases. METEOR started in 2008 and is used as an online daily practice tool for rheumatologists to collect clinical data and calculate disease activity, registering the effectiveness of their treatment practice over time in patients with RA.

Data of both patients with advanced disease and with newly diagnosed RA were collected in a central database. Data is uploaded anonymously and therefore an ethics statement is not required for this study. A more detailed description of the METEOR database was published previously.<sup>22,23</sup> We have used data from the Leiden University Medical Center (LUMC) since

at the time of evaluation the data of this site were most complete with information on both DAS outcomes and anti-rheumatic treatment. Patients were included in METEOR between January 2008 and May 2013. We have selected 1.202 patients (5.157 visits ranging from 1 to 31 visits per patient) where DAS (5.157 visits) as well as information on treatment were available.

### **Outcome variables and determinants**

Treatment adjustment was divided into three categories; 1) dose decrease (either a lower dose or fewer sDMARDs or bDMARDs or corticosteroids, including intra articular injections, compared to the previous visit), 2) stable dose (the same sDMARDs or bDMARDs or corticosteroids, including intra articular injections, and the same dose compared to the previous visit) and 3) treatment change or intensification (higher dose or more or other sDMARDs or bDMARDs or corticosteroids, including intra articular injections, compared to the previous visit).

DAS was classified in four categories, according to the EULAR classification criteria (DAS<1.6 representing clinical remission, DAS>1.6 and  $\leq 2.4$  representing low disease activity, DAS>2.4 and  $\leq 3.7$  representing moderate disease activity, and DAS>3.7 representing high disease activity). For secondary analyses DAS was divided in two categories; DAS  $\leq 2.4$  and DAS>2.4.

We used hypothetical conditions, based on a previous study, in which there was a discrepancy between components of the DAS representing inflammation (joint swelling, laboratory results) or pain (potentially regardless of inflammation) as secondary outcomes.<sup>24</sup> These conditions included 1) cases in which a patient had  $\leq 1$  swollen joints but 2 or more tender joints 2) cases in which a patient had  $\leq 1$  swollen joints but reported a high disease activity ( $\geq 20$  on a visual analogue scale, VASpt) 3) cases in which a patients had  $\leq 1$  swollen joints but an erythrocyte sedimentation rate (ESR)  $\geq 28$  mm/hr 4) cases in which VASpt was  $\geq 20$ mm higher than the physician's score of the patients global disease activity (VASphys) and 5) cases in which the VASphys was  $\geq 20$ mm higher than the VASpt.<sup>23-25</sup>

### **Statistical analyses**

Descriptive statistics were performed using median and interquartile ranges (IQR) for continuous variables, and number and percentages for categorical variables.

The association between DAS and treatment adjustments was assessed using generalized estimating equations (GEE) in order to adjust for the spurious effects of repeated measurements and treatment adjustments within the same subject. The probability of a treatment outcome (decreased, stable or change/intensified) was modelled using the GEE ordinal (cumulative) regression analysis approach.<sup>26</sup> In the regression model, treatment adjustment was the dependent variable, with increase of treatment being the last ordinal category (reference). DAS>2.4 (yes or no) was used as the determinant. We tested the proportional odds for treatment adjustment with crude calculations in cross tables and the goodness-of-fit test. These did not indicate a violation of the proportional odds assumption.<sup>27</sup> In a set of subanalyses, a first GEE binary logistic regression was performed to compare decreased dose versus stable dose. A second binary GEE was performed to compare decreased dose versus increased dose; and a third binary GEE analysis was performed to compare increased dose versus stable dose. In all three analyses DAS>2.4 was the determinant. A fourth GEE was performed to model patients with DAS>2.4 (no intensification versus intensification of treatment) as dependent variable, with erythrocyte sedimentation rate (ESR), SJC, VASpt (patient assessment of global disease activity), TJC and actual treatment as determinants. This model was corrected for gender and age. SPSS version 17.0 was used for the analyses and a two-sided p-value less than 0.05 was considered statistically significant.

## RESULTS

In total 5.157 registered visits in 1.202 patients who were treated with sDMARDs and/or bDMARDs and/or corticosteroids, were available for the analyses. Mean age was 56 (SD: 14) and disease duration was on average 17 months (IQR: 3 to 84). 71% (n=854) of the population were women (table 1). In 1.580 of these 5157 visits (31%) DAS was >2.4 (and in 4% of these, DAS was >3.7), in 3577 visits (69%), DAS was ≤2.4 (in 39% of these DAS was <1.6). In 1.692/5.157 visits (33%) medication was intensified, in 2.881 visits (56%), medication was kept stable, and in 584 visits (11%) medication was tapered or discontinued (table 2). GEE showed that on patient level a higher DAS was only weakly but yet statistically significantly correlated with a change/increase in medication (OR: 1.19, 95%CI: 1.07 to 1.33, table 3). The binary logistic GEE regression showed that in patients with a DAS>2.4 treatment was more often changed/intensified (OR: 1.30, 95%CI: 1.05 to 1.60) than tapered, but not significantly more often changed/intensified than kept stable (table 3).

**Table 1.** Baseline characteristics (visit 1) for patients in the METEOR database.

	<b>Total patients, n=1.202</b>
Female, n (%)	854 (71)
Age (years), mean (SD)	56 (14)
Disease duration (months), median (IQR)	17 (3 to 84)
CCP positive, n (%)	407 (71)
RF present, n (%)	722 (75)
DAS, mean (SD)	2.5 (1.1)
HAQ, mean (SD)	1.0 (0.7)
ESR, median (IQR)	19 (9 to 34)
RAI, median (IQR)	4 (1 to 7)
SJC, median (IQR)	3 (0 to 7)
VAS, median (IQR)	
Patient global	39 (19 to 59)
Doctor global	21 (10 to 40)
Patient pain	43 (23 to 64)

n=number, SD=standard deviation, IQR= interquartile range, VAS=visual analogue scale, CRP= C-reactive protein, ESR= erythrocyte sedimentation rate, DAS=Disease Activity Score, RAI=Ritchie Articular Index, HAQ= Health Assessment Questionnaire, CCP=cyclic cictrullinated peptide antibody, RF=rheumatoid factor

In only 552/1.580 (35%) of the visits in which the patient had a DAS>2.4 medication was indeed changed/intensified, and this percentage was not higher in patients with a DAS>3.7 (table 2).

**Table 2.** Number of visits with decreased, stable or increased dose per level of disease activity based on DAS (Disease Activity Score).

		<b>Decreased dose</b>	<b>Stable dose</b>	<b>Increased dose</b>	<b>Total</b>
<b>DAS</b>	Remission: < 1.6, n (%)	257 (13)	1149 (56)	629 (31)	2035 (100)
	LDA: 1.6 - 2.4, n (%)	179 (12)	852 (55)	511 (33)	1542 (100)
	MDA: 2.4 - 3.7, n (%)	125 (9)	770 (56)	479 (35)	1374 (100)
	HDA: > 3.7, n (%)	23 (11)	110 (53)	73 (35)	206 (100)

n=number, LDA=low disease activity, MDA=moderate disease Activity, HDA=high disease activity.

In 23 visits (11%) in which patients had high disease activity (DAS>3.7) the dose was even decreased. In comparison, in 629 of the 2.035 visits (31%) where patients were in remission (DAS<1.6) medication was still changed/intensified (table 2).

**Table 3.** Association between DAS (Disease Activity Score) and treatment adjustment in METEOR

	DAS>2.4*	
	$\beta$	OR (95% CI)
Overall ordinal correlation**	0.175	1.19 (1.07-1.33)
Stable versus decreased dose***	0.259	1.30 (1.05-1.60)
Increased versus stable dose***	0.096	1.10 (0.97-1.26)
Increased versus decreased dose***	0.36	1.43 (1.17-1.74)

\*Reference category is a DAS  $\leq$  than 2.4. \*\* Ordinal and \*\*\* binary generalized estimating equation regression analysis. DAS > 2.4: higher odds to increase treatment.  $\beta$ =beta, CI=confidence interval.

In the 1.028/1.580 (65%) visits in which patients had a DAS>2.4 treatment was nevertheless not changed/intensified. On the visit level we investigated whether there were discrepancies in DAS components in these 1.028 visits by comparing the median (interquartile range, IQR) tender joint count, swollen joint count, ESR and patient VAS: the median for tender joint count (6, IQR 2 to 8) was slightly higher than the median for swollen joint count (median 4, IQR 2 to 8) (table 4).

**Table 4.** Median of DAS components in visits where medication is not increased when patients have moderate/high disease activity.

DAS>2.4 and medication not increased	
n=1.028 visits, median (IQR)	
VASpt	60.0 (46.0-72.8)
Swollen joint count	4.0 (2.0-8.0)
Tender joint count	6.0 (4.0-8.0)
ESR	25.0 (11.0-38.0)*

\* n=1 missing visit for ESR. n= number, IQR= interquartile range, ESR= erythrocyte sedimentation rate, VASpt=Patient assessment of Global Disease Activity.

In 20% of the visits in which DAS was  $>2.4$  and medication was not changed/intensified, SJC was low ( $\leq 1$ ) while TJC and patient's VAS for global disease activity were high ( $\geq 2$  or  $\geq 20$ , respectively). A higher patient-reported- than physician-assessed global disease activity (difference in VAS  $\geq 20$ mm) was found in 33% of these visits (table 5).

**Table 5.** Number of visits in which there are discrepancies in DAS components in patients with moderate/high disease activity that did not receive treatment intensification.

	<b>DAS<math>&gt;2.4</math> and medication not increased</b>	
	<b>n (%)</b>	<b>Total</b>
SJC $\leq 1$ and TJC $\geq 2$	201 (19.6)	1028
SJC $\leq 1$ and VASpt $\geq 20$	198 (19.3)	1028
SJC $\leq 1$ and ESR $\geq 28$	98 (9.5)	1027
VASpt $\geq 20$ mm higher than VASphys	148 (32.9)	450
VASphys $\geq 20$ mm higher than VASpt	25 (5.6)	450

ESR= erythrocyte sedimentation rate, VASpt= patient assessment of global disease activity, TJC=tender joint count, SJC=swollen joint count, VASphys= physician assessment of global disease activity.

In a GEE binary logistic regression we checked in patients with a DAS $>2.4$  which factors were associated with NO intensification of treatment (intensification of treatment=reference), corrected for age and gender.

These factors were (high) tender joint count (OR: 1.05, 95%CI: 1.01 to 1.10), current treatment with conventional synthetic (cs) DMARD monotherapy (OR: 3.28, 95%CI: 2.40 to 4.48) and combination therapy with methotrexate (MTX) and a bDMARD (OR: 1.93, 95%CI: 1.25 to 2.98) (table 6). Finally, we checked on a visit level whether an improvement in DAS was found compared to the previous visit, but also at the following visits. However, we did not have drug data on all the previous and following visits. In 82 of the available 874 visits (9%) there had been an improvement in DAS (EULAR (European League Against Rheumatism) response moderate or good) compared to the previous visit (table 7).

After a high DAS was followed with no change or increase in medication, at the following visit a good or moderate improvement in DAS was observed in 47 (17%) of the recorded 283 visits.

**Table 6.** Determinants for not increasing medication when patients have moderate/high disease activity, measured by a generalized estimating equation binary logistic regression.\*

	DAS>2.4: medication is not increased vs medication is increased (n=1.574 visits)		
	$\beta$	OR (95%CI)	P-value
ESR	0.00	1.00 (0.99 to 1.01)	0.86
SJC	-0.02	0.99 (0.96 to 1.01)	0.20
VASpt	0.00	1.00 (0.99 to 1.01)	0.98
TJC	0.05	1.05 (1.01-1.10)	<0.01
<b>Actual drug**</b>			
DMARD monotherapy	1.19	3.28 (2.40 to 4.48)	<0.01
MTX + bDMARD	0.66	1.93 (1.25 to 2.98)	<0.01
DMARD combination therapy	0.12	1.12 (0.83 to 1.53)	0.46
DMARD + prednisone	0.03	1.03 (0.67 to 1.57)	0.90

\*Analysis is corrected for gender and age. \*\* Reference category = other drugs. ESR= erythrocyte sedimentation rate, SJC= swollen joint count, TJC=tender joint count, VasPtGlobal=Patient Assessment of global disease activity.

**Table 7.** Number of visits in which patients show improvement in DAS according to the EULAR criteria.

	DAS>2.4, medication	
	not increased	Total
DAS improvement compared to the previous visit		
None: $\leq 0.6$ , N (%)	792 (91)	874
Moderate: 0.6-1.2, N (%)	60 (7)	874
Good: $> 1.2$ , N (%)	22 (2)	874
DAS improved in the following visit		
None: $\leq 0.6$ , N (%)	236 (83)	283
Moderate: 0.6-1.2, N (%)	33 (12)	283
Good: $> 1.2$ , N (%)	14 (5)	283

DAS=Disease Activity Score, EULAR= European League Against Rheumatism.

## DISCUSSION

In this analysis from daily practice observations collected in the METEOR database, we obtained information about how the treat to target recommendation in RA is followed in a single large academic referral centre (LUMC). Most patients had low disease activity or remission (69% of visits  $DAS \leq 2.4$ , 39% even  $< 1.6$ ) during the majority of visits. These percentages approach figures that have been reported in treat-to-target studies such as CAMERA,<sup>28</sup> DREAM<sup>29</sup> and BeSt<sup>30</sup> in which 50-82% achieved low disease activity or remission.

This observation, together with the apperception that DAS-results were indeed measured and recorded, support a conclusion that rheumatologists in the LUMC follow the treat to target approach in daily practice quite well. Since rheumatologists working in the LUMC conducted the Best study, which aims at low disease activity using DAS-steered therapy, this could be expected. Many previous studies, such as TICORA, GUEPARD and ESPOIR showed that a treat to target strategy leads to better clinical outcomes compared to routine care.<sup>5,8</sup>

Since questionnaire-based studies suggest that rheumatologists are aware of the advantages of treatment to target and are willing to apply the treatment recommendations,<sup>14-16</sup> the METEOR tool was developed to help and stimulate rheumatologists to apply a treat to target approach in daily practice.

In spite of a high percentage of patients with  $DAS < 2.4$ , we also found on a patient level, that  $DAS > 2.4$  itself was only weakly associated with a change or intensification of antirheumatic medication (OR: 1.19). In comparison to tapering the dose if  $DAS \leq 2.4$ , the likelihood of increasing the dose was only marginally higher in patients with a  $DAS > 2.4$ . Furthermore, per visit where treatment was not intensified although DAS was higher than 2.4 we found discrepancies in subjective patient outcomes (high tender joint count and/or high patient reported global disease activity on a visual analogue scale) versus physician assessment of disease activity (low swollen joint count). This is reflected by an OR for tender joint count of 1.05 (CI95Q% 1.01-1.1) for not intensifying medication in case of  $DAS > 2.4$ .

This observation may suggest that although rheumatologist may steer treatment decisions by the measured DAS, they consider other explanations of high DAS components, for instance secondary fibromyalgia or irreversible joint damage as explanation for a high tender joint count, which may not respond to a further increase of anti-inflammatory drugs. A discrepancy between subjective patient outcomes and objective physician assessments has been shown in earlier METEOR studies focused on patient's global disease activity (GDA).

Here we found that when patients rate their GDA, they base their opinion more on subjective signs (patient's perception of pain), while physicians put more weight on objective signs (swollen joint count, ESR) when rating GDA of the patient. Also is shown that discrepancies between patients and physicians in GDA assessment are different among countries, suggesting that reporting and acknowledging pain differs per country.<sup>23,31</sup> The METEOR database does not contain information on damage or secondary pain syndromes, or indeed other comorbidities, which may also have held rheumatologists back in increasing treatment where the DAS was high. Nor do we have information on reasons why patients may not have wanted to increase medication.

We also found that the likelihood of treatment intensification in case of DAS>2.4 was less if the patient was currently using csDMARD monotherapy, which may indicate a reluctance among patients to change or expand medication,<sup>32</sup> or methotrexate in combination with a biological agent. The latter may indicate that rheumatologists may be reluctant to change the biologic, as it is currently unclear which is the optimal treatment choice if the first biologic is ineffective.<sup>33-35</sup> Previous studies suggest that an important reason for the rheumatologist to not (yet) intensify the treatment was that they anticipated further improvement on the current medication. We tested this hypothesis but we found only in 9% of the available visits clinical relevant improvement in DAS.

An important limitation to this study is that we do not have data on comorbidities, which might influence the decision of the rheumatologist to change or not change the treatment. Furthermore, we used a rather broad categorization of treatment adjustment without any hierarchy in for instance type or number of drugs that were adjusted, which may have influenced the results. Another limitation is that we have no imaging data, although presence or absence of radiologic damage progression, in clinical practice can influence the decision on treatment intensification. A final restriction is that we used only data from the LUMC since data of other centers/countries were not (sufficiently) available yet. These results may therefore not be generalizable to all patients treated in clinical practice, since perception of pain seems to be country dependent.

In conclusion, we have found a high percentage of patients with remission or a low level of disease activity in the majority of regular registered visits of RA patients to the outpatient clinic of a large academic hospital in the Netherlands. We have also found that a moderate- to high disease activity does not automatically lead to treatment intensification, which may still suggest that Treat-to-Target and EULAR recommendations for the management of patients

with RA are well followed, but also that the doctor is looking critically at possible reasons for elevation of elements of the DAS before deciding on treatment intensification. Future research is needed to study the relationship between disease activity and treatment adjustment using different categorizations, such as type of medication. Also, it will be useful to understand how comorbidities influence the relationship between treatment adjustment and disease activity.

## REFERENCE LIST

- 1 Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. *Clin exp rheum.* 2006;24:S.
- 2 Katchamart W, Bombardier C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. *J rheumatol.* 2010;37:1411-1415.
- 3 Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis.* 2014;73:492-509.
- 4 Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis.* 2014;73:3-5.
- 5 Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *The lancet.* 2004;364:263-269.
- 6 Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. *Ann Rheum Dis.* 2010;69:65-69.
- 7 Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. *Ann Rheum Dis.* 2011;70:611-615.
- 8 Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. *Ann Rheum Dis.* 2005;64:1294-1298.
- 9 Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. *Ann Rheum Dis.* 2012;71:845-850.
- 10 Castrejon I, Pincus T, Soubrier M, et al. GUEPARD treat- to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. *Rheumatology (Oxford).* 2013;52:1890-1897.
- 11 Pope JE, Haraoui B, Rampakakis E, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. *Arthritis Care Res (Hoboken)* 2013;65:1401-1409.
- 12 Van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. *Ann Rheum Dis.* 2011;70:1389-1394.

- 13 Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010;69:631-637.
- 14 Schoels M, Aletaha D, Smolen JS, et al. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. *Ann Rheum Dis*. 2010;69:575-578.
- 15 Park YB, Koh EM, Kim HY, et al. Treating rheumatoid arthritis to target: recommendations assessment questionnaire in Korea. *Clin Rheumatol*. 2013;32:1791-1797.
- 16 Haraoui B, Bensen W, Bessette L, Le CS, et al. Treating rheumatoid arthritis to target: a Canadian physician survey. *J Rheumatol*. 2012;39:949-953.
- 17 Littlejohn G, Roberts L, Arnold M, et al. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. *Int J Rheum Dis*. 2013;16:532-538.
- 18 Kruger K, Karberg K. [Treat-to-target from the perspective of office-based rheumatology]. *Z Rheumatol*. 2011;70:664-669.
- 19 Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. *Arch Intern Med*. 2000;160:2281-2286.
- 20 Huntjens KM, van Geel TA, Blonk MC et al. Implementation of osteoporosis guidelines: a survey of five large fracture liaison services in the Netherlands. *Osteoporos Int*. 2011;22:2129-2135.
- 21 Allen LaPointe NM, Lokhnygina Y, Sanders GD et al. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. *Am Heart J* 2013;166:871-878.
- 22 Koevoets R, Allaart CF, van der Heijde DM, et al. Disease activity monitoring in rheumatoid arthritis in daily practice: experiences with METEOR, a free online tool. *J Rheumatol*. 2010;37:2632-2633.
- 23 Gvozdenovic E, Koevoets R, Wolterbeek R, et al. Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. *Clin Rheumatol*. 2013.
- 24 Markusse IM, Dirven L, Han KH, et al. Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: Reasons for compliance and hesitation. *Arthritis Care Res (Hoboken)*. 2015.
- 25 Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken)*. 2012;64:206-214.
- 26 Fullerton JN, Roberts KJ, Wyse M. Should non-anaesthetists perform pre-hospital rapid sequence induction? an observational study. *Emerg Med J*. 2011;28:428-431.
- 27 Stiger TR, Barnhart HX, Williamson JM. Testing proportionality in the proportional odds model fitted with GEE. *Stat Med*. 1999;18:1419-1433.
- 28 Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis*. 2007;66:1443-1449.

- 29 Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. *Arthritis Rheum.* 2011;63:2865-2872.
- 30 Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. *Ann Rheum Dis.* 2011;70:1039-1046.
- 31 Gvozdencovic E, Wolterbeek R, Allaart CF, et al. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. *J Clin Rheumatol.* 2015;21:349-354.
- 32 Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. *Arthritis Rheum.* 2007;56:2135-2142.
- 33 Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. *Rheumatology (Oxford).* 2007;46:1191-1199.
- 34 Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. *Arthritis Rheum.* 2006;54:600-606.
- 35 Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? *Ann Rheum Dis.* 2004;63:607-608.

